Key Segments:
By Test Type
• Dry Blood Spot (DBS) Tests
• Hearing Screening
• Critical Congenital Heart Disease (CCHD) Screening
• DNA-based / Genetic Screening
By Technology
• Tandem Mass Spectrometry (TMS)
• PCR / Molecular Assays
• Immunoassays (ELISA, FIA, etc.)
• Next-Generation Sequencing (NGS)
By Product Type
• Reagents & Assay Kits
• Instruments / Analyzers
• Hearing Screening Devices
• Consumables & Accessories
By Application
• Metabolic Disorders
• Hormonal Disorders
• Hematological Disorders
• Hearing & CCHD Disorders
• Genetic / Rare Diseases
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Newborn Screening Market was valued at USD 2.33 billion in 2025.
The market is expected to reach USD 5.03 billion by 2035.
The market is projected to grow at a CAGR of 8.01% from 2026 to 2035.
Growth is driven by rising awareness of early disease detection, increasing birth rates, technological advancements in screening methods, and supportive government initiatives.
Newborn screening helps detect genetic, metabolic, hormonal, and functional disorders such as phenylketonuria (PKU), congenital hypothyroidism, and cystic fibrosis.